EMJ GOLD: Pharma news, views and analysis S12 E01: The 2026 pharma forecast: Unknowns and personal goals
9 snips
Feb 19, 2026 
Yacin Marzouki, omnichannel expert who shapes customer journeys and aligns global strategy with local execution. He frames AI as pharma’s biggest unknown and opportunity. Short takes cover AI governance, costs and privacy, pricing and policy volatility, and the push to better activate existing content across channels.
AI Snips
Chapters
Transcript
Episode notes
Global Politics Reshape Pharma Planning
- Global political volatility can reshape launches, access and supply chains across markets.
- Emma Charles warns this complexity makes long-range planning far harder for pharma.
Regulatory Unknowns Around AI
- Regulatory approaches to AI remain unclear and will influence publishing, evidence and compliance.
- Dheepa Chari notes guidance is coming but its speed and universality are unknown.
Pricing And Exclusivity Are Major Wildcards
- Policy changes, tariffs and loss of exclusivity will converge to create pricing and access uncertainty.
- Mary Stutts highlights that evolving market dynamics complicate forecasting and strategy.